These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 2420012

  • 1. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease.
    Santoro A, Viviani S, Valagussa P, Bonfante V, Bonadonna G.
    Semin Oncol; 1986 Mar; 13(1 Suppl 1):23-6. PubMed ID: 2420012
    [Abstract] [Full Text] [Related]

  • 2. Third-line salvage chemotherapy in Hodgkin's disease.
    Bonadonna G, Viviani S, Valagussa P, Bonfante V, Santoro A.
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):23-5. PubMed ID: 2579440
    [Abstract] [Full Text] [Related]

  • 3. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA.
    J Clin Oncol; 2003 Feb 15; 21(4):607-14. PubMed ID: 12586796
    [Abstract] [Full Text] [Related]

  • 4. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
    Piga A, Ambrosetti A, Todeschini G, Cetto G, Perona G, Cellerino R.
    Cancer Treat Rep; 1984 Feb 15; 68(7-8):947-51. PubMed ID: 6204754
    [Abstract] [Full Text] [Related]

  • 5. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP.
    Santoro A, Viviani S, Villarreal CJ, Bonfante V, Delfino A, Valagussa P, Bonadonna G.
    Cancer Treat Rep; 1986 Mar 15; 70(3):343-8. PubMed ID: 2420444
    [Abstract] [Full Text] [Related]

  • 6. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP.
    Semin Oncol; 1990 Feb 15; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of advanced stage Hodgkin disease with CCNU, etoposide and prednimustine (CEP)].
    Illés A, Bányai A, Szegedi G.
    Orv Hetil; 1994 May 29; 135(22):1187-90. PubMed ID: 8015814
    [Abstract] [Full Text] [Related]

  • 8. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.
    Carella AM, Congiu AM, Gaozza E, Mazza P, Ricci P, Visani G, Meloni G, Cimino G, Mangoni L, Coser P.
    J Clin Oncol; 1988 Sep 29; 6(9):1411-6. PubMed ID: 2458439
    [Abstract] [Full Text] [Related]

  • 9. [Treatment with CEP (CCNU, VP-16 and prednimustine) in Hodgkin's disease resistant to CVPP and ABVD. Results in 21 patients].
    Cervantes F, Reverter JC, Bladé J, Montserrat E, Rozman C.
    Sangre (Barc); 1988 Jun 29; 33(3):184-7. PubMed ID: 2459787
    [No Abstract] [Full Text] [Related]

  • 10. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
    Andrieu JM, Colonna P.
    J Clin Oncol; 1998 Jun 29; 16(6):2283. PubMed ID: 9626234
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
    Diehl V, Fuchs M, GHSG.
    Transfus Apher Sci; 2007 Aug 29; 37(1):37-41. PubMed ID: 17714996
    [Abstract] [Full Text] [Related]

  • 15. Combination chemotherapy of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, dacarbazine and vinblastine (ABDV).
    Case DC, Young CW, Lee BJ.
    Cancer; 1977 Apr 29; 39(4):1382-6. PubMed ID: 66972
    [Abstract] [Full Text] [Related]

  • 16. Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy.
    Krikorian JG, Portlock CS, Rosenberg SA.
    Cancer; 1978 Jun 29; 41(6):2107-11. PubMed ID: 77716
    [Abstract] [Full Text] [Related]

  • 17. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM, Michelangelo Foundation, Gruppo Italiano di Terapie Innovative nei Linfomi, Intergruppo Italiano Linfomi.
    N Engl J Med; 2011 Jul 21; 365(3):203-12. PubMed ID: 21774708
    [Abstract] [Full Text] [Related]

  • 18. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA, Hum GJ, Sheehan WW, Ryden VM, Bateman JR.
    Cancer Treat Rep; 1983 May 21; 67(5):413-9. PubMed ID: 6342771
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Advanced Hodgkin's disease: ABVD is better, yet is not good enough!
    Diehl V.
    J Clin Oncol; 2003 Feb 15; 21(4):583-5. PubMed ID: 12586791
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.